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1. BACKGROUND 
The three principal areas of application of hor- 
mone antagonists are: clinical, diagnostic, and 
delineation of hormone action ([l-5] for reviews). 
Inhibition of synthesis of glucocorticoids in the 
adrenal cortex was attempted nearly three decades 
ago using metyrapone and aminogluthemide 
derivatives [3,5], and more recently with an- 
timycotic agents [6,7]. Some 45 years ago an- 
drogens and superandrogens R 2999 and R 4841 
[8-l 11, progesterone [12,13], oestrogens [8,14], 
and insulin [2] were used to oppose clinical effects 
of glucocorticoids, despite numerous side effects. 
Physiological actions of corticoids in animals 
could also be antagonized [1% 191 but the response 
was equivocal [ 111. 
It is generally admitted that adrenocorticoid 
hormone action proceeds via a soluble, 
cytoplasmic receptor in the target cell [l-5]. Thus, 
an ‘ideal’, specific, antagonist, devoid of side ef- 
fects, would have to be sought by structural 
modification of the native hormone in relation to 
the receptor structure. 
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2. STRUCTURE-AFFINITY 
CONSIDERATIONS 
Two types of structural modifications of the 
steroid molecule have been attempted, namely in 
the C and the D rings. It is clear that an alcohol 
function in the 1 I,& position is required for agonist 
activity. The 1 la-hydroxycortisol, the 11-keto 
derivative (cortisone), and the 1 1-deoxy analogue 
(cortexolone) of cortisol are antagonists in various 
systems in vitro [2,3,8]. Some 20 years ago, cortex- 
olone was the only antiglucocorticoid effective on 
both the liver and thymus in vivo in adrenalec- 
tomised animals [2,3,8], but was transformed into 
an agonist after hydroxylation in the lip position 
in the adrenals of intact animals [l-3]. The 1 1-oxa 
derivatives of both cortisol and prednisolone 
(fig.1) cannot be hydroxylated in the 11 position 
and retained the antagonist activity in vivo [20]. 
The receptor binding correlated with biological ac- 
tivity in these studies. 
Another school of thought lays greater emphasis 
on modifications in the D ring of the steroid for 
genesis of antagonists than on the C ring [3,5]. The 
17-21 acetonides of cortisol and cortexolone are 
only marginally active derivatives [21] and 17-21 
oxetanones of cortisol and dexamethasone are only 
weak antagonists of enzyme induction in 
hepatoma cells in vitro [20]. 
D ring substitution led to the synthesis of 
mesylates of cortisol and dexamethasone (fig. 1) 
that form affinity labels by an irreversible 
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Fig. 1. Structural formulae of some leading antiglucocorticoids. 
blockade of the cytosolic receptor [20]. They are 
only partial antagonists in vitro and very toxic in 
vivo [20]. The 17@-carboxamides antagonised en- 
zyme induction in hepatoma cells, but were ap- 
parently destined to oblivion since then [21]. 
3. THE EPOXIDE PATHWAY 
The discovery of the epoxide pathway at Roussel 
laboratories [3,5] opened up a whole new area in 
the antiglucocorticoid field. The chemical reaction 
involves a modification in both the 11 position and 
the ketolic side chain [22,23]. A large number of 
derivatives has been synthesized starting from 
RU 26988, the ideal glucocorticoid agonist. These 
were subsequently used as potent probes to map 
the steroid-binding domain (SBD) on the receptor, 
and to prove the determining role of the 11 posi- 
tion in the agonist vs the antagonist action, 
although the A ring is believed to be important in 
binding to the receptor [3,4]. 
Thus, all 1 l,&aryl derivatives are devoid of pro- 
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gesterone receptor (PR) binding activity whereas 
the vinyl derivative has strong affinity for PR and 
is also a full glucocorticoid receptor (GR) agonist 
[4,5,8,24]. Substitution in the para position has a 
moderate effect on the SBD but meta substitution 
decreases affinity for PR leading to some dissocia- 
tion between binding to the two types of receptors. 
Finally, the introduction of a bulky residue in the 
p-diphenyl configuration does not reduce binding 
to either GR or PR, suggesting that both these 
receptors contained a hydrophobic pocket 
[3,5,22,23]. Actually, it is the size of this substi- 
tuent which determines the agonist vs the an- 
tagonist activity, since the synthesis of the 
1 l&(4-dimethylaminophenyl) derivative led to the 
discovery of the most potent antisteroid for both 
the glucocorticoid and the progesterone series 
[3,5,8,22,23]. What follows is essentially a 
catalogue of the success story of this newly syn- 
thesized derivative dubbed RU 38486, or simply 
RU 486, now named Mifepristone (1 l&(4-di- 
methylaminophenyl)- 17,&hydroxy- 17a-(propyl- l- 
ynyl)estra-4,9-dien-3-one). 
4. A NEW RECEPTOR PROBE 
In view of receptor heterogeneity [24,25], which 
is not due to receptor fragmentation by en- 
dogenous proteases [26-281, it was important to 
establish whether the agonists would saturate the 
same receptor populations as the antagonists. 
Mifepristone was bound to the same population of 
GR as various agonists in hepatoma cells [ 121, 
thymocytes [29-311, and rat liver [32,33]. 
The affinity of Mifepristone was found to be less 
than that of the agonist triamcinolone acetonide 
(TA) for rat liver GR [33] but higher than that of 
dexamethasone for GR in rat thymus [3,30,31] and 
in hepatoma cells [ 12,311. The rate of dissociation 
of Mifepristone from the activated GR was much 
faster than with the agonist in thymus [29-311, as 
well as rat liver [33], cytosol and this was partially 
prevented by molybdate and phosphate buffers 
[29]. Paradoxically, Mifepristone-bound PR gave 
more stable complexes at 35°C than those obtained 
with progesterone in chick oviduct cytosol [34]. 
Whereas rat liver GR-Mifepristone complexes 
could be heat-activated just as well as TA-GR com- 
plexes [33], rat thymocyte GR could be activated 
only partially [30]. Recently, rat kidney 
mineralocorticoid receptor could be activated just 
as well in the presence of the agonist aldosterone as 
with the antagonist RU 26752 [35]. Thus, receptor 
activation is not an exclusive property of hormonal 
steroids, contrary to earlier studies [l-5]. 
Nuclear translocation of GR bound to 
Mifepristone was impaired in isolated rat thymus 
nuclei in vitro whereas agonist-GR was avidly 
bound to nuclei [30]. Similarly, murine thymoma 
Mifepristone-GR complexes exhibited diminished 
binding to murine mammary tumour virus DNA 
promoter as compared to the agonist-GR com- 
plexes [36]. These results cast doubt on the in- 
tranuclear localization of Mifepristone by 
autoradiography [37] where chemical analysis of 
the nuclear bound radioactivity was required to 
rule out rapid metabolic conversions in vivo [38]. 
Thus, intranuclear events seem more important 
than those in the cytosol for the physiological ac- 
tion of Mifepristone. 
Recently, a 90 kDa protein was found to be a 
common component of both the GR and the PR 
[39] which recalls a similar hydrophobic pocket in 
the steroid-binding domain of the receptor for 
these two classes of hormones [3,5,8,24]. Contrary 
to the current notion, rat liver GR-Mifepristone 
complexes did not bind to the idiotype antibody 
obtained in the rabbit with TA-BSA, implying dif- 
ferences in the conformation and topology of the 
active site [40]. Chick oviduct, too, exhibited two 
separate binding sites, one each for progesterone 
and Mifepristone, contrary to the situation in calf 
uterus where both materials saturated an identical 
receptor [34]. Mifepristone did not bind to 
transcortin and was a better ligand than dex- 
amethasone for chick oviduct GR [41]. All these 
results largely confirm some of our earliest studies 
on receptor multiplicity [25,26]. 
5. CELLULAR ACTION OF MIFEPRISTONE 
The anabolic action (increased RNA, protein 
synthesis, enzyme induction, gluconeogenesis) of 
glucocorticoids in the liver is to be contrasted with 
their catabolic action (decreased macromolecular 
synthesis, fragmentation, cell death) in lymphatic 
tissues such as the thymus (reviews in [l-4]). 
In adrenalectomised rats, Mifepristone abol- 
ished the induction of tryptophan pyrrolase (TP) 
and tyrosine transaminase (TT), as well as 
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gluconeogenesis, in response to synthetic glucocor- 
ticoids [3,32]. More important, the basal level of 
these parameters ,was not influenced in control 
animals given Mifepristone alone. Increase in TP 
levels, seen as a result of endogenous cor- 
ticosterone secretion following ethanol administra- 
tion, was also reversed by Mifepristone [42]. 
Although cultured hepatoma cells are much in 
use, neoplastic transformation permits the expres- 
sion of only the TT gene [l-4]. The induction of 
this enzyme was reversed by Mifepristone in a 
dose-dependent manner in two hepatoma cell lines 
[43,44]. In one cell line, Mifepristone even ex- 
hibited an agonist activity [43], contrary to the 
liver [3,32]. No agonist activity, however, was 
noted when dexamethasone-mediated in uction of 
y-glutamyl transferase was studied in these cells 
[45]. Enhanced metabolism of the antagonist in 
liver cells, as compared to the transformed cells, 
may be partially responsible for this conflict [38]. 
In any event, these caution against reckless ex- 
trapolation in vivo of results obtained in vitro and 
further obviate the validity of hepatoma cells as a 
viable model for normal liver functions. 
The catabolic effect of glucocorticoids (inhibi- 
tion of uridine incorporation) was reversed by 
Mifepristone in thymocytes in vitro [3,32] at a time 
when the formation of dexamethasone-receptor 
complexes in the cytoplasm and the translocation 
of this complex into the nuclei were also impaired 
by the antagonist [32]. Mifepristone also reversed 
dexamethasone-mediated inhibition of growth in a 
human cervix cell line [46], of the synthesis of pro- 
collagen mRNA in chick skin fibroblasts [47], and 
of the induction of Epstein-Barr virus in Daudi 
lymphoma cells [48]. 
The inhibitory effect of dexamethasone on the 
humoral as well as the cellular immune response 
was overcome by Mifepristone [49]. Similarly, this 
material reversed hydrocortisone-mediated inhibi- 
tion of prostacyclin synthesis in rat aorta [50]. It 
also overcame the inhibition of prostacyclin and 
thromboxane A2 after the administration of pro- 
gesterone which is known to be a glucocorticoid 
antagonist [l-5], possibly due to its antiprogestin 
activity 150,511. 
In the pituitary from the neonatal rat which, 
contrary to the adult animal, totally lacks the 
mineralocorticoid receptor, aldosterone exhibits 
corticotropic activity and inhibits ACTH release 
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which is reversed by Mifepristone [52]. On the 
other hand, glucocorticoids can induce hyperten- 
sion in the rat and this can also be antagonised by 
Mifepristone which exhibits no intrinsic activity of 
its own [53]. Finally, hydrocortisone was shown to 
increase angiotensinogen synthesis in Reuber 
hepatoma cells in vitro and this too could be 
prevented by Mifepristone [54]. These data suggest 
that glucocorticoids may be involved in the regula- 
tion of arterial tension in the mammal although so 
far this has been supposed to be controlled mostly 
by the brain mineralocorticoid receptor [55]. In 
fact, oral administration of Mifepristone abolished 
vasoconstriction produced by topical application 
of glucocorticoids in normal men [56]. In addition, 
it also lowered the intraocular pressure in the rab- 
bit eye [57]. 
Clinically, Mifepristone administration reversed 
the atrophy of the levator ani muscle in the rat seen 
in response to endogenous or exogenous glucocor- 
ticoids [58,59]. Mifepristone also reduced symp- 
toms of Cushing’s syndrome due to ectopic ACTH 
secretion [60,61]. 
Administration of Mifepristone at midnight in 
the human inhibits the dexamethasone blockade of 
the pituitary adrenal axis [62,63]. When given 
alone at 10 a.m., it increased cortisol levels at 
4 p.m. which returned to normal by 8 a.m. the 
following morning [64], but had no effect if ad- 
ministered at 4 p.m. [63]. Increased ACTH and 
cortisol levels were also observed in the monkey 
[65,66]. Mifepristone-mediated isinhibition of the 
dexamethasone-blocked retrocontrol was also evi- 
dent in pituitary cells in vitro where it exhibited no 
intrinsic activity [67]. Thus, Mifepristone may be 
used as a diagnostic tool for the pituitary-adrenal 
axis in various situations [64,68]. 
6. FUTURE TRENDS 
It is evident from the foregoing that the epoxide 
pathway, leading to the synthesis of Mifepristone 
has provided an entirely new vision in the an- 
tiglucocorticoid field. It has no inherent agonist or 
antagonist activity, no known toxicity or side ef- 
fects, and high metabolic degradation albeit of low 
availability in vivo. Thus, it comes close to being 
an ideal glucocorticoid antagonist, despite 
associated antiprogestin activity [51]. For the first 
time, then, an antiglucocorticoid, active in vivo, 
Volume 217, number 2 FEBS LETTERS June 1987 
has finally been found. It is currently being used as 
a starting point for the synthesis of more specific 
antiglucocorticoids and of steroids with inverse 
C-13 configuration [69,70]. The in vivo 
significance of receptor heterogeneity [24,71,72], 
of endogenous proteases [26-281, and of 
phosphorylation [5,73], can all be fruitfully 
scrutinized with Mifepristone. Since it can sensitize 
mice to endotoxin lethality for prolonged periods 
of time [71], Mifepristone appears to possess ef- 
fects that do not necessarily involve the glucocor- 
ticoid receptor and this should be kept in mind in 
future studies. 
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